Clinical-trial findings suggested that combining chemotherapy with radiation therapy is the best treatment for people with a low-grade form of brain cancer.
A phase III trial of Halaven (eribulin) in patients with soft tissue sarcoma demonstrated a statistically significant extension in overall survival over the comparator treatment dacarbazine, the primary endpoint of the study. No other systemic treatment for locally advanced or metastatic soft tissue sarcoma has been reported to extend overall survival in a phase III study, according to Halaven's sponsor, Eisai.
FDA granted accelerated approval to Farydak (panobinostat) for the treatment of patients with multiple myeloma.
Preliminary results from the phase II STAND trial showed a robust immune response with Provenge (sipuleucel-T) that continued two years after completing treatment in men with biochemically-recurrent prostate cancer.
An independent data monitoring committee recommended unblinding the phase III HELIOS trial, which is evaluating Imbruvica in combination with bendamustine and rituximab in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, following clinically meaningful and statistically significant treatment benefit.
FDA granted accelerated approval to Ibrance (palbociclib) to treat metastatic breast cancer.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Investigators with The Cancer Genome Atlas Research Network discovered genomic differences in head and neck cancers caused by infection with the human papillomavirus. Researchers also uncovered new smoking-related cancer subtypes and potential new drug targets, and found numerous genomic similarities with other cancer types.
An analysis comparing sentinel lymph node biopsy procedures using Lymphoseek (technetium Tc 99m tilmanocept) injection and vital blue dye to filtered sulfur colloid and VBD in breast cancer patients showed that Lymphoseek patients had significantly fewer sentinel lymph nodes removed per procedure (mean: 1.85 vs. 3.24; p < 0.0001).
Decades after undergoing cranial irradiation for childhood cancer, researchers at St. Jude Children’s Research Hospital found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life. The study included 748 St. Jude survivors of leukemia, brain and other cancers whose treatment included brain... […]
